Second-line antituberculosis drugs: Current knowledge, recent research findings and controversies

Simple item page
dc.contributor.authorSchaaf H.S.
dc.contributor.authorSeddon J.A.
dc.contributor.authorCaminero J.A.
dc.date.accessioned2011-10-13T16:59:24Z
dc.date.available2011-10-13T16:59:24Z
dc.date.issued2011
dc.description.abstractThe treatment of drug-resistant tuberculosis (TB) necessitates the use of drugs that are poorly understood, less efficacious and often associated with more adverse effects than those used to treat drugsusceptible TB. Many of these second-line compounds were discovered over 50 years ago and were soon superseded by more effective and better tolerated drugs. However, in treating drug-resistant TB, we must re-evaluate these drugs as the available armamentarium of drugs is so limited. New medications, as well as established medications not previously used against TB, need to also be considered. As diagnostic techniques improve and more cases of drug-resistant TB are diagnosed, clinicians must be familiar with these second-line drugs to enable them to successfully manage patients. This article reviews the literature, often limited and sometimes elderly, regarding the second-line drugs. It also examines recent research findings and identifies areas of controversy and discussion. It comments on the laboratory, pharmacokinetic and pharmacodynamic properties of the drugs as well as discussing adverse effects. Copyright © 2011 S. Karger AG, Basel.
dc.description.versionReview
dc.identifier.citationProgress in Respiratory Research
dc.identifier.citation40
dc.identifier.citationhttp://www.scopus.com/inward/record.url?eid=2-s2.0-80052928912&partnerID=40&md5=6041e9e1780df81956d66733b2a7f802
dc.identifier.issn14222140
dc.identifier.other10.1159/000324382
dc.identifier.urihttp://hdl.handle.net/10019.1/17094
dc.titleSecond-line antituberculosis drugs: Current knowledge, recent research findings and controversies
dc.typeReview
Files
Collections
Stellenbosch University - Scopus Publications